Exclusive Interview with Oramed Pharmaceuticals Inc. CEO, Nadav Kidron on www.CEOcast.com
June 06 2007 - 8:47AM
PR Newswire (US)
JERUSALEM, June 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals,
Inc. (OTC Bulletin Board: ORMP ; FTSE: OJU) invites everybody to
join Nadav Kidron on http://www.ceocast.com/ to discuss the future
of Oramed Pharmaceuticals Inc., and update the investment community
on the present status of the company. The interview will take place
at 3pm Eastern time on Thursday, June 7. If you have any specific
questions to ask, please email them to for the interviewer to ask
on Thursday morning. To hear the interview in its entirety, please
visit http:/// http://www.ceocast.com/. Please click on the company
name to the left of the site, or look for Oramed in the archives at
a later date. CEO Nadav Kidron stated, "We have had a steady
progress over the past 2 months and are looking forward to speaking
with our supportive shareholders." About Oramed Pharmaceuticals,
Inc: Oramed Pharmaceuticals Inc. is an Israeli company focused on
the development of oral delivery solutions based on proprietary
technology. Diabetes is one of the most rapidly growing diseases in
the world and is one that requires constant and often unpleasant
monitoring and drug therapy regimen. Oramed is currently developing
an orally ingestible soft gel insulin capsule for the treatment of
diabetes. The Company is also pursuing the development of oral
delivery solutions for other drugs and vaccines. For more
information on Oramed Pharmaceuticals please visit our website at
http://www.oramedpharma.com/. Legal Notice Regarding Forward
Looking Statements This news release contains statements, which may
constitute "forward-looking statements". Those statements include
statements regarding the intent, belief or current expectations of
Oramed as well as the assumptions on which such statements are
based. Forward-looking statements in this release include: that we
are currently developing an orally soft gel insulin capsule for the
treatment of diabetes; and that we are also pursuing the
development of oral delivery solutions for other drugs and
vaccines. Factors which may significantly change or prevent our
forward looking statements from fruition include that we may be
unsuccessful in developing any products; we may be unable to raise
funds and resources to pursue research and development; we may be
unable to successfully defend our patents from infringement by
third parties, there is a risk that our patents may be subsequently
shown to be invalid or infringe the patents of others; we may be
unable to attract or retain our key employees, consultants and
advisors, our products may never gain FDA or other regulatory body
approval for human consumption and we may be unable to successfully
commercialize our future products. Readers should refer to our most
recent 10-KSB filed on Edgar and the 8-K announcing our acquisition
of the Oramed technology filed March 8, 2006. DATASOURCE: Oramed
Pharmaceuticals, Inc. CONTACT: Investor Relations Contact: Vinisha
Agnihotri for Oramed Pharmaceuticals, Inc., +1-646-467-2252, Web
site: http://www.ceocast.com/ http://www.oramedpharma.com/
Copyright